SYRE Q1 2018 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+53.8% YoY

Gross Profit

$00.0% margin

Operating Income

-$8M-546.0% margin

Net Income

-$8M-537.7% margin

EPS (Diluted)

$-12.17

QoQ Revenue Growth

+1.9%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$8M

Stock-Based Comp.

$835,000

Balance Sheet

Total Assets

$50M

Total Liabilities

$6M

Stockholders' Equity

$44M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$982,000	+53.8%
Gross Profit	$0	$0	—
Operating Income	-$8M	-$6M	-30.2%
Net Income	-$8M	-$6M	-30.0%